

REMARKS

Applicants have amended claims 10-16 to recite that the serine/threonine and tyrosine kinases are protein kinases. Support for this amendment is found throughout the specification. See, e.g., page 1, line 17. Applicants have further amended claim 10 to clarify that the binding of a compound to the mutant protein kinase is compared to the binding of the compound to the second serine/threonine protein kinase or second tyrosine protein kinase. Support for this amendment is found throughout the specification. See, e.g., page 7, lines 20-24.

Applicants have amended claim 11 to define a MAP kinase as a mitogen activated protein kinase. Applicants have amended claim 12 to define ERK2 and JNK3 as extracellular-signal regulated kinase 2 and Jun N-terminal kinase 3, respectively. Support for these amendments are found, *inter alia*, at page 2, lines 21-22 and 28-29.

Applicants have further amended claims 10 and 12-16 to improve their form.

None of these amendments adds new matter. Their entry is requested.

Respectfully submitted,

Karen E. Brown

James F. Haley, Jr. (Reg. No. 27,794)

Attorney for Applicants

Karen E. Brown (Reg. No. 43,866)

Agent for Applicants

c/o Fish & Neave

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000

Fax: (212) 596-9090

003 F 55 5-4-73-4745